This document is a published patent application from the USPTO for novel therapeutic compounds identified as orexin-1 receptor antagonists. The application, filed on September 25, 2025, and published as US20260085060A1, describes compounds with a specific structural formula (I), processes for their synthesis, pharmaceutical compositions containing them, and their potential use in treating diseases linked to orexin-1 receptor activity.

This is a patent application, not a final rule or guidance. It does not impose immediate compliance obligations. However, it signals potential future intellectual property rights and market exclusivity for compounds targeting orexin-1 receptors, which may be relevant for pharmaceutical companies and drug manufacturers in their research and development strategies.